Spyre Therapeutics reported that its lead anti‑α4β7 antibody SPY001 achieved its primary endpoint in the Phase 2 SKYLINE Part A induction study for moderate‑to‑severely active ulcerative colitis. The 12‑week study showed a statistically significant 9.2‑point reduction in the Robarts Histopathology Index (RHI) (p < 0.0001), a 40 % clinical remission rate by modified Mayo score, and a 51 % endoscopic improvement rate. Safety was consistent with the α4β7 class, with only six treatment‑emergent adverse events and one serious adverse event deemed unrelated to the drug.
The results position SPY001 as a class‑leading anti‑α4β7 therapy. Its extended half‑life is engineered to enable quarterly or biannual subcutaneous dosing, a substantial convenience advantage over the bi‑weekly infusion schedule of the current standard, Entyvio. The magnitude of the RHI reduction and the high remission and endoscopic improvement rates suggest that SPY001 may deliver superior histologic and clinical benefit while maintaining a favorable safety profile.
"SPY001 was designed to improve upon vedolizumab's proven activity in IBD by matching its epitope and potency while increasing target coverage through an extended half‑life and greater induction dosing. Our data today support the hypothesis that this approach could lead to a best‑in‑class anti‑α4β7 product across safety, efficacy, and convenience," said Deanna Nguyen, M.D., Senior Vice President of Clinical Development and SKYLINE study lead.
"Beyond SPY001's potential as a monotherapy, we continue to believe that its gut‑selective mechanism makes it an ideal backbone for combination therapy alongside our cytokine‑targeting investigational antibodies SPY002 (anti‑TL1A) or SPY003 (anti‑IL23). We have begun enrolling these combinations globally and look forward to unveiling proof‑of‑concept data next year," added Nguyen.
The announcement was met with a strong market reaction, with analysts noting the data as class‑leading and highlighting the potential for a best‑in‑class product. The results reinforce Spyre’s strategy of developing long‑acting monoclonal antibodies and support the company’s broader pipeline of cytokine‑targeting candidates.
Recruitment for Part A was closed and enrollment has begun for Part B, which will evaluate SPY001, SPY002, and SPY003 as monotherapies and as pairwise combinations (SPY120, SPY130, SPY230). The company plans to report proof‑of‑concept induction data for the combination cohorts next year, further expanding its potential therapeutic portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.